IFNB1 (118-132) Human deimmunised
SSLHLKRYYGRVLHY-acid
Description
Application Data
Description
-
IFNB1 (118-132) is a recognised human CD4+ T cell epitope. The isoleucine residue has been changed to valine, resulting in a deimmunised peptide.
Application Data
-
Data Sheet Data Sheet Material Safety Data Sheet (MSDS)Catalogue number crb1001729 Molecular Weight 1891.0 Sequence (one letter code) SSLHLKRYYGRVLHY-acid
Sequence (three letter code) H-Ser-Ser-Leu-His-Leu-Lys-Arg-Tyr-Tyr-Gly-Arg-Val-Leu-His-Tyr-OH
Purity >95% Citations Siegel et al., (2022). Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics. Pharmaceutics, 14: 2672. doi: 10.3390/pharmaceutics14122672.
References Yeung et al., (2004). Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. J. Immunol. Res., 172(11): 6658. doi: 10.4049/jimmunol.172.11.6658.
Manufactured in: United Kingdom Recombinant human interferon-beta (IFNB) is a therapeutic for specific stages of multiple sclerosis (MS). However, a significant portion of patients develop neutralising antibodies within two years which prevent the clinical efficacy of the treatment; this was correlated to a specific rise in IgG. Sequencing of IFNB1 revealed CD4+ T cell epitope residues (118-132) that contain critical T cell activation residues. Identifying these sequences allows them to be manipulated to provide new interferon treatments that reduce the capacity to induce neutralising antibodies in MS patients. In addition, the critical residue isoleucine has been mutated to valine and shown to reduce the immunological response to this epitope. This IFNB1 (118-132) epitope can be used for immunological investigations as a deimmunised version of the epitope. In addition, it can be used as a control for T cell activation and antibody recognition via immunoassays and immunohistochemistry. This may provide further insights into specific haplotypes correlating to IFNB responses in MS treatment.
